Inhibrx Past Earnings Performance

Past criteria checks 0/6

Inhibrx's earnings have been declining at an average annual rate of -37%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 37.9% per year.

Key information

-37.0%

Earnings growth rate

-15.3%

EPS growth rate

Biotechs Industry Growth	-14.6%
Revenue growth rate	-37.9%
Return on equity	-2,344.0%
Net Margin	-15,207.8%
Last Earnings Update	31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Inhibrx makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:1RK Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
31 Mar 24	2	-271	33
31 Dec 23	2	-241	29
30 Sep 23	0	-189	27
30 Jun 23	1	-172	24
31 Mar 23	1	-163	22
31 Dec 22	2	-145	21
30 Sep 22	5	-125	19
30 Jun 22	7	-111	17
31 Mar 22	7	-94	14
31 Dec 21	7	-82	12
30 Sep 21	7	-78	11
30 Jun 21	11	-78	10
31 Mar 21	13	-75	8
31 Dec 20	13	-76	7
30 Sep 20	10	-75	6
30 Jun 20	6	-74	6
31 Mar 20	6	-68	6
31 Dec 19	13	-51	6
30 Sep 19	15	-40	6
30 Jun 19	15	-30	6
31 Mar 19	14	-26	5
31 Dec 18	9	-31	5
30 Sep 18	7	-35	4
31 Dec 17	8	-19	3
31 Dec 16	7	-8	2

Quality Earnings: 1RK is currently unprofitable.

Growing Profit Margin: 1RK is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1RK is unprofitable, and losses have increased over the past 5 years at a rate of 37% per year.

Accelerating Growth: Unable to compare 1RK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1RK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.8%).

Return on Equity

High ROE: 1RK has a negative Return on Equity (-2344.01%), as it is currently unprofitable.

Inhibrx Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023)

Full year 2023 earnings released: US$5.12 loss per share (vs US$3.62 loss in FY 2022)

Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022)

Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022)

First quarter 2023 earnings released: US$1.12 loss per share (vs US$0.80 loss in 1Q 2022)

Full year 2022 earnings released: US$3.62 loss per share (vs US$2.15 loss in FY 2021)

Recent updates

First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023)

Full year 2023 earnings released: US$5.12 loss per share (vs US$3.62 loss in FY 2022)

No longer forecast to breakeven

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022)

Inhibrx, Inc. Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx, Inc. announced that it has received $200.000633 million in funding

Inhibrx, Inc. announced that it expects to receive $199.999961 million in funding

New major risk - Share price stability

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022)

Inhibrx, Inc. Grants Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2023 earnings released: US$1.12 loss per share (vs US$0.80 loss in 1Q 2022)

Full year 2022 earnings released: US$3.62 loss per share (vs US$2.15 loss in FY 2021)

High number of new and inexperienced directors

Inhibrx, Inc. Updates Efficacy and Safety Data from Ongoing Phase 1 INBRX-109 Expansion Cohorts for the Treatment of Chondrosarcoma

Third quarter 2022 earnings released: US$0.90 loss per share (vs US$0.54 loss in 3Q 2021)

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Second quarter 2022 earnings released: US$0.97 loss per share (vs US$0.55 loss in 2Q 2021)

Inhibrx, Inc. Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105

High number of new and inexperienced directors

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

Inhibrx, Inc. to Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2022 earnings released: US$0.80 loss per share (vs US$0.51 loss in 1Q 2021)

High number of new and inexperienced directors

Inhibrx, Inc. Announces Formation of A Scientific Advisory Board for Its INBRX-101 program

Inhibrx, Inc., Annual General Meeting, May 25, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Inhibrx, Inc. Announces Initial Phase 1 Dose Escalation Results for INBRX-106

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.77 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.55 loss per share (vs US$0.98 loss in 2Q 2020)

Inhibrx, Inc.(NasdaqGM:INBX) dropped from Russell 3000E Value Index

Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study

First quarter 2021 earnings released: US$0.51 loss per share (vs US$1.05 loss in 1Q 2020)

Inhibrx, Inc. Announces Results from the Single Agent Dose Escalation of the Phase 1 Study of INBRX-105

Full year 2020 earnings released: US$3.01 loss per share (vs US$2.83 loss in FY 2019)

Revenue beats expectations

New 90-day low: €18.30

Inhibrx, Inc. Announces U.S. Food and Drug Administration Granted Fast Track Designation to INBRX-109

Inhibrx, Inc. Announces Results from Part 1 of the Phase 1 Dose Escalation Trial of Inbrx-106

Arecor's Partner Inhibrx Exercises Its Option to License A New Formulation Developed by Arecor

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta